Neena Verma

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

Shyam Sundar, Prabhat Kumar Sinha, Madhukar Rai et al. · The Lancet · 2011 · 335 citations

Veterinary Medicine, Infectious Diseases, Pharmacology +11

Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis

Sujit Bhattacharya, Prabhat Kumar Sinha, Shyam Sundar et al. · The Journal of Infectious Diseases · 2007 · 260 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Liposomal Amphotericin B for Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients: 2-Year Treatment Outcomes in Bihar, India

P. K. Sinha, Johan van Griensven, Krishna Pandey et al. · Clinical Infectious Diseases · 2011 · 83 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

Sakib Burza, Prabhat Kumar Sinha, Raman Mahajan et al. · PLoS neglected tropical diseases · 2014 · 67 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +14

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India

Sakib Burza, Prabhat Kumar Sinha, Raman Mahajan et al. · PLoS neglected tropical diseases · 2014 · 65 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17